Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel Free LLIT Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Lianluo Smart (LLIT) Competitors

Compare

LLIT vs. INFU, NSPR, HSAQ, TMDIF, and PETV

Should you be buying Lianluo Smart stock or one of its competitors? The main competitors of Lianluo Smart include InfuSystem (INFU), InspireMD (NSPR), Health Sciences Acquisitions Co. 2 (HSAQ), Titan Medical (TMDIF), and PetVivo (PETV). These companies are all part of the "medical" sector.

How does Lianluo Smart compare to InfuSystem?

Lianluo Smart (NASDAQ:LLIT) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

InfuSystem has a consensus price target of $15.00, suggesting a potential upside of 78.36%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Lianluo Smart.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lianluo Smart
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
InfuSystem
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

InfuSystem has higher revenue and earnings than Lianluo Smart.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lianluo Smart$380K205.27-$4.45MN/AN/A
InfuSystem$143.44M1.18$870K$0.3822.13

InfuSystem has a net margin of 1.12% compared to Lianluo Smart's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Lianluo Smart's return on equity.

Company Net Margins Return on Equity Return on Assets
Lianluo SmartN/A N/A N/A
InfuSystem 1.12%2.78%1.41%

28.8% of Lianluo Smart shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 22.9% of Lianluo Smart shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, InfuSystem had 5 more articles in the media than Lianluo Smart. MarketBeat recorded 5 mentions for InfuSystem and 0 mentions for Lianluo Smart. InfuSystem's average media sentiment score of 0.35 beat Lianluo Smart's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company Overall Sentiment
Lianluo Smart Neutral
InfuSystem Neutral

Lianluo Smart has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Summary

InfuSystem beats Lianluo Smart on 12 of the 14 factors compared between the two stocks.

How does Lianluo Smart compare to InspireMD?

Lianluo Smart (NASDAQ:LLIT) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Lianluo Smart has higher earnings, but lower revenue than InspireMD.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lianluo Smart$380K205.27-$4.45MN/AN/A
InspireMD$10.85M4.97-$19.92M-$0.73N/A

Lianluo Smart has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Lianluo Smart's return on equity of 0.00% beat InspireMD's return on equity.

Company Net Margins Return on Equity Return on Assets
Lianluo SmartN/A N/A N/A
InspireMD -413.96%-69.42%-57.68%

InspireMD has a consensus price target of $4.50, suggesting a potential upside of 291.30%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Lianluo Smart.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lianluo Smart
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
InspireMD
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

28.8% of Lianluo Smart shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 22.9% of Lianluo Smart shares are held by company insiders. Comparatively, 34.1% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, InspireMD had 10 more articles in the media than Lianluo Smart. MarketBeat recorded 10 mentions for InspireMD and 0 mentions for Lianluo Smart. InspireMD's average media sentiment score of 0.22 beat Lianluo Smart's score of 0.00 indicating that InspireMD is being referred to more favorably in the news media.

Company Overall Sentiment
Lianluo Smart Neutral
InspireMD Neutral

Lianluo Smart has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

InspireMD beats Lianluo Smart on 9 of the 14 factors compared between the two stocks.

How does Lianluo Smart compare to Health Sciences Acquisitions Co. 2?

Lianluo Smart (NASDAQ:LLIT) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Lianluo Smart.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lianluo Smart$380K205.27-$4.45MN/AN/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Company Net Margins Return on Equity Return on Assets
Lianluo SmartN/A N/A N/A
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

28.8% of Lianluo Smart shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 22.9% of Lianluo Smart shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Lianluo Smart's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Lianluo Smart Neutral
Health Sciences Acquisitions Co. 2 Neutral

Lianluo Smart has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.

Summary

Lianluo Smart beats Health Sciences Acquisitions Co. 2 on 4 of the 6 factors compared between the two stocks.

How does Lianluo Smart compare to Titan Medical?

Lianluo Smart (NASDAQ:LLIT) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

In the previous week, Titan Medical had 1 more articles in the media than Lianluo Smart. MarketBeat recorded 1 mentions for Titan Medical and 0 mentions for Lianluo Smart. Lianluo Smart's average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score.

Company Overall Sentiment
Lianluo Smart Neutral
Titan Medical Neutral

Titan Medical has higher revenue and earnings than Lianluo Smart.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lianluo Smart$380K205.27-$4.45MN/AN/A
Titan Medical$17.63M1.81$6.95M$0.055.61

Lianluo Smart's return on equity of 0.00% beat Titan Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Lianluo SmartN/A N/A N/A
Titan Medical N/A -82.31%-51.47%

Lianluo Smart has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

28.8% of Lianluo Smart shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 22.9% of Lianluo Smart shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Lianluo Smart beats Titan Medical on 5 of the 9 factors compared between the two stocks.

How does Lianluo Smart compare to PetVivo?

Lianluo Smart (NASDAQ:LLIT) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Lianluo Smart's average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score.

Company Overall Sentiment
Lianluo Smart Neutral
PetVivo Neutral

Lianluo Smart has higher earnings, but lower revenue than PetVivo.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lianluo Smart$380K205.27-$4.45MN/AN/A
PetVivo$1.05M27.38-$10.95M-$0.38N/A

Lianluo Smart has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Lianluo Smart's return on equity of 0.00% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
Lianluo SmartN/A N/A N/A
PetVivo -902.82%-4,813.07%-281.78%

Lianluo Smart has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

28.8% of Lianluo Smart shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 22.9% of Lianluo Smart shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lianluo Smart beats PetVivo on 7 of the 9 factors compared between the two stocks.

Get Lianluo Smart News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLIT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLIT vs. The Competition

Export
MetricLianluo SmartSurgical & Medical Instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$78.00M$42.70M$6.18B$12.29B
Dividend YieldN/A1.08%2.78%5.25%
P/E RatioN/A15.0128.7027.27
Price / Sales205.2729.83506.8864.14
Price / CashN/A18.8843.3053.97
Price / Book-59.8014.2910.006.82
Net Income-$4.45M-$20.10M$3.54B$332.87M

Lianluo Smart Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLIT
Lianluo Smart
N/A$35.28
-0.1%		N/A+838.3%$78.00M$380KN/A6
INFU
InfuSystem
4.1646 of 5 stars		$10.34
+0.7%		$15.00
+45.1%		+88.8%$208.81M$143.44M172.36410
NSPR
InspireMD
3.117 of 5 stars		$1.25
-2.3%		$5.00
+300.0%		-54.6%$60.02M$8.98MN/A50
HSAQ
Health Sciences Acquisitions Co. 2
N/A$4.13
-0.5%		N/A+65.7%$46.31MN/AN/A4
TMDIF
Titan Medical
N/A$0.33
+2.3%		N/A+12.3%$37.63M$17.63MN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LLIT) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
This Biotech Just Flipped From Story to Execution
Avai Bio, Inc. (OTCQB: AVAI) has launched production of its new Master Cell Bank alongside Austrianova, markin...
Equiscreen | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel